CCR5 and neoplasm: S6 Table lists other examples along with GPCRs that have reduced expression compared to normal tissue. Importantly, of the 203 GPCRs with increased expression in one or more tumors, 77 are targets for approved drugs. These include ADORA2B, CCR5, and F2R, which are overexpressed in 27, 27, and 26 tumor subtypes, respectively. S6 and S2 Tables provide further details regarding such druggable GPCRs.